{"gene":"ESR2","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1996,"finding":"ESR2 (ERβ) was cloned as a novel estrogen receptor with high conservation in the DNA-binding domain (96%) and ligand-binding domain (58%) relative to ERα. Transient transfection of ESR2 with an ERE-based reporter in CHO cells demonstrated 17β-estradiol-induced transactivation, and ICI-164384 (an ERα antagonist) also acts as a potent antagonist for ESR2. ESR2 shows lower transactivation levels than ERα under equivalent conditions.","method":"Degenerate PCR cloning, sequence homology analysis, transient transfection reporter assay, pharmacological antagonism","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro transactivation assay with reporter gene and pharmacological characterization; foundational cloning paper replicated widely","pmids":["8769313"],"is_preprint":false},{"year":1999,"finding":"ERβ and ERα adopt distinct ligand-dependent conformational changes when bound to estradiol versus 4-OH tamoxifen, as revealed by differential peptide binding surfaces on each receptor complex. These conformation-specific peptides can discriminate between ERα and ERβ ligand complexes, providing a structural basis for isoform- and ligand-specific biological activities.","method":"Affinity selection of peptides to probe receptor conformation (peptide phage display / affinity selection) on apo-ER and ligand-bound ER complexes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct structural/conformational probing using peptide affinity selection with multiple ligands and both receptor isoforms","pmids":["10097152"],"is_preprint":false},{"year":2000,"finding":"ERβ (ESR2) modulates ERα activity in the uterus: BERKO (ERβ knockout) mice exhibit elevated progesterone receptor, increased Ki-67, and exaggerated E2 responses (uterine enlargement, elevated C3, IL-1β, VEGF, IGF-1), demonstrating that ERβ has an antiproliferative, modulatory function opposing ERα-mediated actions.","method":"ERβ knockout mouse model (BERKO), immunohistochemistry, protein quantification, hormonal challenge experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in vivo with multiple orthogonal phenotypic readouts; replicated concept across labs","pmids":["10823946"],"is_preprint":false},{"year":2001,"finding":"ERβ (ESR2), when expressed via adenoviral vector in ER-negative MDA-MB-231 breast cancer cells, localizes to the nucleus, transactivates ERE-reporter constructs in the presence of E2, induces pS2, TGFα, and p21 expression, inhibits cell proliferation in a ligand-independent manner, and decreases cell motility and invasion. Unlike ERα, ERβ does not regulate c-myc expression.","method":"Adenoviral vector-mediated expression, RT-PCR, Western blot, immunocytochemistry, ERE-reporter transactivation assay, proliferation assay, invasion/motility assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays in a clean ER-null cell system with defined readouts","pmids":["11517191"],"is_preprint":false},{"year":2003,"finding":"ERα and ERβ form functional heterodimers when coexpressed; ERβ exhibits inhibitory action on ERα-mediated gene expression in multiple cell-type and promoter contexts, opposing ERα transcriptional activity.","method":"Transient transfection, reporter gene assays, coexpression studies (review summarizing experimental evidence)","journal":"Molecular interventions","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — review article summarizing experimental data from multiple labs, but this paper itself is a review; underlying experiments are multiply replicated","pmids":["14993442"],"is_preprint":false},{"year":2004,"finding":"Both ERα and ERβ can independently mediate E2-induced proliferation in mammary gland epithelial cells. ERβ facilitates the return of ERα to the nucleus after E2-induced nuclear export, thereby restoring E2 responsiveness. After E2 treatment, ERα is lost from nuclei of epithelial cells within 4 h; in ERβ-knockout mice, re-entry of ERα is delayed by an additional 24 h. Tamoxifen treatment retains ERα but loses ERβ from the nucleus.","method":"BrdUrd incorporation assay, immunohistochemistry with subtype-specific antibodies, ERβ-knockout (ERβ−/−) mouse model, hormonal challenge","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model combined with multiple imaging and proliferation readouts in vivo","pmids":["14762170"],"is_preprint":false},{"year":2005,"finding":"The E2-ERβ complex rapidly and persistently activates p38/MAPK, leading to caspase-3 activation and PARP cleavage, driving cells into apoptosis. In contrast to E2-ERα, the E2-ERβ complex does not activate ERK/MAPK or PI3K/AKT survival pathways. These non-genomic signaling differences were demonstrated in cells containing endogenous (HepG2, DLD1) or transfected (HeLa) ERβ or ERα.","method":"Transient transfection, kinase activation assays (ERK/MAPK, p38/MAPK, PI3K/AKT), caspase-3 activity assay, PARP cleavage, cell growth/apoptosis measurements in multiple cell lines","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal signaling assays across several cell lines with endogenous and exogenous receptor","pmids":["15389627"],"is_preprint":false},{"year":2006,"finding":"ESR2 isoforms β2, β4, and β5 lack a functional helix 12 (required for coactivator binding); they cannot form homodimers and have no intrinsic transactivation activity. However, they heterodimerize with ERβ1 and enhance its transactivation in a ligand-dependent manner. ERβ1 is the obligatory partner in ERβ dimers; a single functional helix 12 per dimer is sufficient for gene transactivation. ERβ1 preferentially forms heterodimers with other isoforms under estrogen but not phytoestrogen stimulation.","method":"Molecular modeling, transient transfection reporter assays, dimerization assays (co-immunoprecipitation), isoform-specific expression from prostate cell line","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — molecular modeling with functional validation by reporter assay and dimerization experiments, multiple isoforms tested","pmids":["16938840"],"is_preprint":false},{"year":2008,"finding":"ERβ (ESR2) suppresses ERα gene expression in endometriotic stromal cells by binding to non-classical AP-1 and Sp1 motifs in ERα promoters A and C, and to a classic ERE in promoter B (shown by ChIP). ERβ knockdown increases ERα mRNA and protein; ERβ overexpression decreases ERα mRNA and protein. ERβ also regulates cell cycle progression in endometriotic stromal cells.","method":"siRNA knockdown, overexpression, RT-PCR, Western blot, chromatin immunoprecipitation (ChIP), promoter analysis","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct ERβ binding to ERα promoters, supported by reciprocal gain/loss-of-function experiments","pmids":["19001520"],"is_preprint":false},{"year":2008,"finding":"ERβ (ESR2) mediates anxiety-regulation: lower-dose E2 treatment exerts anxiolytic effects partially through ERβ in female mice, as ERβ-knockout (betaERKO) mice show attenuated anxiolytic responses in the social investigation test compared to wild-type, while high-dose E2 anxiogenic effects are ERβ-independent.","method":"ERβ-knockout mouse model, light-dark transition test, elevated plus-maze test, social investigation test, estradiol dose-response","journal":"Physiology & behavior","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic KO with behavioral readout, single lab, partial effect only at low doses","pmids":["18996135"],"is_preprint":false},{"year":2008,"finding":"ESR2 loss-of-function in male mice (Esr2−/−) does not alter EAE disease severity, while heterozygosity (Esr2+/−) increases disease severity with earlier onset (heterotic effect). Bone marrow chimera experiments established that the heterotic effect at Esr2 in regulating EAE severity is a function of the non-hematopoietic compartment. ESR2 genotype-dependently regulates IL-6 and TNF-α cytokine secretion.","method":"ERβ-knockout and heterozygous mouse models, EAE immunization, reciprocal bone marrow chimeras, cytokine assays (proliferation, IL-2, IFN-γ, IL-6, TNF-α, MCP-1)","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via reciprocal bone marrow chimeras with defined cytokine readouts","pmids":["15161628"],"is_preprint":false},{"year":2008,"finding":"ERβ (ESR2) attenuates ERα-mediated transcriptional activation of the BRCA2 promoter: ERβ interacts with ERα and CBP/p300, forming a weak activating complex that competes with the ERα-CBP/p300-p68/p72-MyoD complex for Sp1 binding sites on the BRCA2 promoter, reducing histone acetylation and BRCA2 transcription.","method":"Co-immunoprecipitation, ChIP, reporter gene assay, site-directed mutagenesis of Sp1 sites, Western blot for histone acetylation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP, and reporter assays with mechanistic dissection of complex composition","pmids":["18765668"],"is_preprint":false},{"year":2013,"finding":"ERβ (ESR2) expression specifically in oligodendrocytes (OLs) is required for the neuroprotective and pro-myelination effects of the ERβ agonist DPN in EAE mice. Conditional deletion of ERβ in OLs prevented DPN-induced decrease in EAE clinical disease, blocked DPN-induced attenuation of demyelination, impaired axon conduction recovery, and abolished PI3K/Akt/mTOR pathway activation in OLs, while BDNF upregulation by DPN was preserved.","method":"Conditional Cre-loxP knockout of ESR2 in oligodendrocytes, EAE model, electrophysiology (axon conduction), immunostaining, Western blot (PI3K/Akt/mTOR), ELISA (BDNF)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with multiple orthogonal mechanistic readouts","pmids":["24191028"],"is_preprint":false},{"year":2014,"finding":"ESR2 activation (using the selective agonist diarylpropionitrile, DPN) modifies the distribution of daily locomotor activity, delays acrophase of wheel running, and advances the time of activity onset in ovariectomized female mice; DPN also attenuates photic phase-shifting in the early subjective night. These effects are distinct from ESR1-mediated effects on total activity and amplitude.","method":"Ovariectomy, selective ESR1/ESR2 agonist administration (PPT vs. DPN), wheel-running activity measurement, free-running period analysis, light-pulse phase-response curve","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection using selective agonists with quantitative circadian readouts, single lab","pmids":["24735329"],"is_preprint":false},{"year":2016,"finding":"A germline ESR2 frameshift mutation (c.948delT) causes loss of ERβ expression and results in unopposed ERα-mediated transcriptional activation. In vitro, this ESR2 mutation leads to increased cellular proliferation, activation of ERE-containing reporters, and increased RET promoter-driven expression (the RET promoter contains three EREs). ERβ normally represses ERα-mediated activation of the RET promoter.","method":"Exome resequencing, in vitro reporter assay (ERE and RET promoter), cell proliferation assay, immunostaining for RET protein in tumor tissue","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional mutation analysis with in vitro reporter assay and in vivo tumor immunostaining confirming mechanism","pmids":["26945007"],"is_preprint":false},{"year":2017,"finding":"E2/ERβ suppresses isoproterenol (ISO)-induced cardiomyocyte hypertrophy by inhibiting Ca2+-calcineurin signaling: ERβ overexpression and/or E2 treatment blocked ISO-induced upregulation of ANP, BNP, p-CaMKII, calcineurin, p-GATA4, and NFATc3, and inhibited NFATc3 nuclear translocation. The calcineurin inhibitor CsA confirmed calcineurin as the key mediator; calcium chelation (BAPTA) blocked the anti-hypertrophic effect, establishing that ERβ acts by reducing Ca2+ influx and thereby inhibiting calcineurin to activate I-1 protein, suppress PP1, and enhance PLB phosphorylation to restore SR Ca2+ cycling.","method":"ERβ overexpression in H9c2 cardiomyoblasts, Western blot, immunofluorescence (NFATc3 translocation), pharmacological inhibitors (CsA, BAPTA), ISO-induced hypertrophy model","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain-of-function overexpression with multiple pharmacological epistasis experiments and mechanistic pathway dissection","pmids":["28863192"],"is_preprint":false},{"year":2017,"finding":"E2/ERβ inhibits isoproterenol-induced myocardial cell apoptosis by promoting calcineurin protein degradation through activation of the PI3K/Akt/MDM2 signaling pathway, suppressing cytochrome c release and downstream apoptotic markers.","method":"ERβ overexpression in H9c2 cells, ISO-induced apoptosis model, Western blot (calcineurin, PI3K/Akt/MDM2, cytochrome c, apoptosis markers)","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function in cell model with defined signaling pathway, single lab, single method type","pmids":["28441761"],"is_preprint":false},{"year":2018,"finding":"ESR2 regulates granulosa cell genes essential for follicle maturation and ovulation. Both null and DNA-binding domain (DBD) mutant ESR2 rats fail to ovulate, demonstrating that ESR2 transcriptional activity (via DNA binding) is indispensable for ovulation. RNA-seq identified 1,696 differentially expressed genes in Esr2-mutant granulosa cells including steroidogenesis, follicle maturation, and ovulation pathways; Kiss1 was identified as an ESR2-regulated gene in granulosa cells.","method":"Esr2-null and DBD-mutant rat models, exogenous gonadotropin stimulation, granulosa cell isolation, RNA-sequencing, molecular pathway analysis","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — two distinct genetic models (null and DBD mutant) with genome-wide transcriptomic readout establishing canonical transcriptional mechanism","pmids":["29580824"],"is_preprint":false},{"year":2018,"finding":"ESR2 is required for gonadotropin-induced Kiss1 expression in granulosa cells. ESR2 binds directly to estrogen response elements (EREs) in the Kiss1 promoter and both upstream and downstream enhancers (shown by ChIP). ESR2 overexpression induces Kiss1 promoter activity, and ERE mutation abolishes this induction. Gonadotropins induce ERK2-mediated ESR2 phosphorylation, upregulate AP-1 factors (FOSL2, JUNB), which synergistically activate the Kiss1 promoter together with ESR2.","method":"ChIP, reporter gene/luciferase assay, ERE site-directed mutagenesis, ESR2 overexpression, kinase phosphorylation assays, Esr2-null rat model","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP demonstrating direct binding, reporter assay with mutagenesis, genetic KO confirmation, and signaling pathway dissection","pmids":["30277501"],"is_preprint":false},{"year":2020,"finding":"ESR2 acts as a gatekeeper to maintain the primordial follicle reserve by suppressing follicle activation. Esr2-null (Esr2−/−) rats show increased activation of primordial follicles (not increased total follicle number), premature ovarian senescence, reduced serum AMH and estradiol. ESR2-specific antagonist (PHTPP) increases activated follicle counts; ESR2 agonist (DPN) decreases activation. ESR1 loss does not increase primordial follicle activation (ESR2-specific effect). ESR2 loss augments AKT, ERK, and mTOR pathway activation in both granulosa cells and oocytes, suggesting a direct intrafollicular regulatory mechanism via canonical transcriptional function (DNA-binding domain mutant also shows increased activation).","method":"Esr2-null and DBD-mutant rat models, selective agonist/antagonist treatment, follicle counting, hormone measurement (AMH, estradiol), Western blot (AKT, ERK, mTOR phosphorylation)","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — two genetic models plus pharmacological manipulation, multiple orthogonal mechanistic readouts","pmids":["32141511"],"is_preprint":false},{"year":2020,"finding":"ESR2 (ERβ) generates an all-exon deleted mouse (Esr2ΔE1-10). Female Esr2ΔE1-10 mice are subfertile at young age and become infertile/severely subfertile by ~6 months. Ovaries are smaller with very few corpora lutea (defect in ovulation), and estradiol levels are reduced at diestrus. Male Esr2ΔE1-10 mice are fertile, establishing that ERβ is required for female but not male reproductive function.","method":"CRISPR/Cas9 full-gene deletion, fertility tracking (litter number, litter size), ovarian histomorphology, hormone measurement (serum estradiol)","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — complete gene deletion model with sex-specific reproductive phenotype and hormonal mechanistic readout","pmids":["32703416"],"is_preprint":false},{"year":2009,"finding":"ERβ agonist ERB-041 inhibits LPS-induced iNOS production in peritoneal macrophages of endometriosis by suppressing NF-κB nuclear translocation (preventing p65 nuclear accumulation), but does not act through the ERK pathway (ERK activity is not repressed by ER activation). Peritoneal macrophages from endometriosis patients express higher levels of ERβ relative to ERα.","method":"RT-PCR, immunoblot (ERα/ERβ expression, iNOS, p65, ERKs), pharmacological treatment with ERB-041 (ERβ agonist) and U0126 (ERK inhibitor), LPS stimulation","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological agonist with pathway-specific inhibitors and defined mechanistic readout, single lab","pmids":["19447495"],"is_preprint":false},{"year":2019,"finding":"ERβ (ER-β) regulates FATP1/SLC27A1 expression in breast cancer cells: treatment with estradiol plus the ERβ antagonist PHTPP blocked estradiol-induced FATP1/SLC27A1 upregulation, fatty acid uptake, and cell viability in four breast cancer cell lines, establishing ERβ as the receptor mediating these estrogen effects on fatty acid transport.","method":"Pharmacological ERβ antagonism (PHTPP), estradiol treatment, RT-qPCR/protein expression, fatty acid uptake assay, cell viability assay in 4 breast cancer cell lines","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection in multiple cell lines with multiple readouts, single lab","pmids":["31575907"],"is_preprint":false},{"year":2024,"finding":"ESR2 acts as a negative transcription factor to down-regulate miR-10a transcription in the prefrontal cortex; miR-10a-5p in turn suppresses BDNF expression. This ESR2→miR-10a-5p→BDNF axis affects synaptic plasticity (synapse-related proteins SYP, SYN, PSD95 and glutamate receptor expression) and contributes to postpartum depressive-like behavior. Bioinformatics, in vivo mouse models, cell transfection, and primary neuron cultures were used to validate the pathway.","method":"Bioinformatics, in vivo behavioral studies (postpartum depression mouse model), cell transfection, primary neuron culture, stereotactic/intranasal antagomir delivery, Western blot (synaptic proteins), luciferase reporter","journal":"Research (Washington, D.C.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vivo and in vitro methods establishing transcriptional regulatory axis; single lab","pmids":["39588356"],"is_preprint":false},{"year":2024,"finding":"ESR2 activation by LXA4 inhibits ferroptosis in fibroblast-like synoviocytes (FLSs) through the ESR2/LPAR3/Nrf2 axis: LXA4 upregulates ESR2, LPAR3, and GPX4 in FLSs. LPAR3 overexpression upregulates GPX4, Nrf2, and SOD1 while downregulating MMP13 and MMP3; LPAR3 knockdown reverses these changes. The ESR2 antagonist PHTPP partially reversed the beneficial effects of exercise on synovial and cartilage pathology in a rat KOA model.","method":"GSE29746 dataset analysis, synovial tissue sampling from KOA patients, LPAR3 overexpression/knockdown in vitro, rat MIA-induced KOA model, ESR2 antagonist (PHTPP) treatment, Western blot (GPX4, Nrf2, SOD1, MMPs)","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function for LPAR3 with defined molecular readouts, pharmacological ESR2 antagonism in vivo; single lab","pmids":["38754271"],"is_preprint":false}],"current_model":"ESR2 (ERβ) is a ligand-activated nuclear receptor that, upon 17β-estradiol binding, transactivates ERE-containing target genes (including Kiss1, BRCA2, and others) through direct DNA binding requiring its DNA-binding domain and helix 12; it forms homodimers (with ERβ1 as obligatory partner) and heterodimers with ERα and other ERβ isoforms, generally opposing ERα-mediated transcriptional activation via competition at promoter binding sites; non-genomically, the E2-ERβ complex activates p38/MAPK to drive apoptosis while suppressing ERK/MAPK and PI3K/AKT survival signaling; in the ovary ESR2 is indispensable for follicular maturation, ovulation, and maintenance of the primordial follicle reserve via AKT/ERK/mTOR pathway suppression; in the myocardium ERβ limits hypertrophy and apoptosis by modulating Ca²⁺-calcineurin-PI3K/Akt/MDM2 signaling; in oligodendrocytes ERβ mediates pro-myelination neuroprotection via PI3K/Akt/mTOR; and in macrophages ERβ suppresses NF-κB nuclear translocation to reduce iNOS expression."},"narrative":{"mechanistic_narrative":"ESR2 (ERβ) is a ligand-activated nuclear receptor that, upon 17β-estradiol binding, transactivates ERE-containing target genes through a DNA-binding domain that is highly conserved with ERα, but with intrinsically lower transactivation potency [PMID:8769313]. Distinct ligand-dependent conformational changes distinguish ERβ from ERα and underlie isoform-specific activity [PMID:10097152]. A recurring theme across tissues is that ERβ acts as an antiproliferative modulator that opposes ERα: in the uterus ERβ restrains ERα-driven proliferative responses [PMID:10823946], in ER-negative breast cancer cells reintroduced ERβ induces pS2, TGFα, and p21 while inhibiting proliferation, motility, and invasion [PMID:11517191], and it directly attenuates ERα-mediated transcription by competing at promoter binding sites — repressing the BRCA2 promoter through an ERβ–CBP/p300 complex that displaces the activating ERα complex from Sp1 sites [PMID:18765668], and binding AP-1, Sp1, and ERE motifs in the ERα promoter to suppress ERα expression itself [PMID:19001520]. Loss of ERβ produces unopposed ERα signaling and increased proliferation, and a germline ESR2 frameshift mutation (c.948delT) abolishing ERβ expression de-represses the ERE-containing RET promoter [PMID:26945007]. Receptor dimerization is constrained by isoform structure: ERβ2/β4/β5 isoforms lack a functional helix 12 and cannot homodimerize or transactivate alone, but heterodimerize with the obligatory ERβ1 partner to enhance its ligand-dependent activity [PMID:16938840]. ERβ also signals non-genomically, with the E2–ERβ complex selectively activating p38/MAPK to drive caspase-3-dependent apoptosis while failing to engage the ERK and PI3K/AKT survival pathways activated by ERα [PMID:15389627]. In the ovary ERβ is indispensable for follicular maturation and ovulation through its DNA-binding transcriptional activity, directly driving Kiss1 expression via promoter and enhancer EREs in granulosa cells [PMID:29580824, PMID:30277501], and it acts as a gatekeeper of the primordial follicle reserve by suppressing AKT/ERK/mTOR-dependent follicle activation [PMID:32141511]. Beyond reproduction, ERβ limits cardiomyocyte hypertrophy and apoptosis by inhibiting Ca²⁺–calcineurin signaling and promoting PI3K/Akt/MDM2-mediated calcineurin degradation [PMID:28863192, PMID:28441761], and mediates pro-myelination neuroprotection in oligodendrocytes through PI3K/Akt/mTOR [PMID:24191028]. A germline ESR2 frameshift mutation has been linked to tumor formation through loss of ERα repression [PMID:26945007].","teleology":[{"year":1996,"claim":"Established that a second estrogen receptor exists, defining ERβ as a ligand-activated transcription factor distinct from ERα with weaker transactivation.","evidence":"Degenerate PCR cloning, sequence homology, and ERE-reporter transactivation in CHO cells with pharmacological antagonism","pmids":["8769313"],"confidence":"High","gaps":["Endogenous target genes not yet identified","Physiological tissue role undefined","Basis for lower transactivation vs ERα unexplained"]},{"year":1999,"claim":"Resolved why ERβ and ERα behave differently by showing each adopts distinct ligand-dependent conformations, providing a structural basis for isoform- and ligand-specific activity.","evidence":"Peptide affinity selection probing apo- and ligand-bound receptor surfaces with estradiol and 4-OH tamoxifen","pmids":["10097152"],"confidence":"High","gaps":["No atomic-resolution structure reported here","Functional consequence of conformations in vivo not tested"]},{"year":2000,"claim":"Defined ERβ's in vivo role as an antiproliferative modulator opposing ERα-mediated estrogen responses in the uterus.","evidence":"BERKO knockout mice with immunohistochemistry, protein quantification, and hormonal challenge","pmids":["10823946"],"confidence":"High","gaps":["Molecular mechanism of opposition not resolved here","Direct vs indirect effects on ERα targets unclear"]},{"year":2001,"claim":"Showed ERβ directly suppresses tumor cell proliferation and invasion in an ERα-null context, distinguishing its target gene program (induces p21, pS2, TGFα; not c-myc) from ERα.","evidence":"Adenoviral ERβ expression in MDA-MB-231 cells with reporter, proliferation, and invasion assays","pmids":["11517191"],"confidence":"High","gaps":["Ligand-independent growth inhibition mechanism not defined","Single cell line"]},{"year":2003,"claim":"Consolidated that ERβ forms functional heterodimers with ERα and inhibits ERα-mediated transcription across promoter and cell-type contexts.","evidence":"Review summarizing transfection and reporter coexpression studies","pmids":["14993442"],"confidence":"Medium","gaps":["Review-level synthesis, not new primary data","Structural detail of heterodimer not addressed"]},{"year":2004,"claim":"Revealed a chaperone-like function whereby ERβ facilitates ERα nuclear re-entry after E2-induced export, restoring estrogen responsiveness.","evidence":"BrdU labeling, subtype-specific immunohistochemistry, and ERβ-knockout mice with hormonal challenge","pmids":["14762170"],"confidence":"High","gaps":["Molecular machinery of ERα re-import unknown","Whether ERβ acts directly on ERα trafficking untested"]},{"year":2006,"claim":"Defined the dimerization rules of ERβ isoforms, establishing ERβ1 as the obligatory partner and showing helix-12-deficient isoforms modulate rather than independently activate.","evidence":"Molecular modeling with reporter and co-immunoprecipitation dimerization assays across isoforms","pmids":["16938840"],"confidence":"High","gaps":["In vivo relevance of isoform heterodimers not established","Tissue-specific isoform stoichiometry unknown"]},{"year":2005,"claim":"Distinguished ERβ from ERα non-genomically, showing E2–ERβ activates p38/MAPK to drive apoptosis rather than engaging survival ERK/PI3K-AKT pathways.","evidence":"Kinase activation, caspase-3, and PARP cleavage assays across HepG2, DLD1, and HeLa cells","pmids":["15389627"],"confidence":"High","gaps":["Membrane receptor pool/scaffold mediating signaling unidentified","Link to genomic ERβ outputs unclear"]},{"year":2008,"claim":"Mechanistically dissected ERβ repression of ERα-driven BRCA2 transcription via competition at Sp1 sites and reduced histone acetylation.","evidence":"Reciprocal Co-IP, ChIP, reporter assays, and Sp1-site mutagenesis","pmids":["18765668"],"confidence":"High","gaps":["Generalizability beyond BRCA2 promoter untested here","Coactivator quantitation indirect"]},{"year":2008,"claim":"Showed ERβ directly suppresses ERα gene expression by binding non-classical AP-1/Sp1 and classic ERE motifs in ERα promoters, creating a feedback loop controlling estrogen sensitivity.","evidence":"siRNA knockdown, overexpression, ChIP, and promoter analysis in endometriotic stromal cells","pmids":["19001520"],"confidence":"High","gaps":["Cofactors at AP-1/Sp1 sites not identified","Restricted to endometriotic stromal context"]},{"year":2008,"claim":"Extended ERβ function to behavior and neuroimmune regulation, implicating it in anxiolysis and in non-hematopoietic control of autoimmune neuroinflammation.","evidence":"ERβ-knockout/heterozygous mice in anxiety tests and EAE with reciprocal bone marrow chimeras and cytokine assays","pmids":["18996135","15161628"],"confidence":"Medium","gaps":["Anxiolytic effect partial and dose-restricted, single lab","Non-hematopoietic cell type mediating EAE heterosis unresolved"]},{"year":2009,"claim":"Identified an anti-inflammatory mechanism whereby ERβ agonism suppresses macrophage iNOS by blocking NF-κB p65 nuclear translocation independent of ERK.","evidence":"ERB-041 and U0126 treatment with immunoblotting in endometriosis peritoneal macrophages","pmids":["19447495"],"confidence":"Medium","gaps":["Direct ERβ–NF-κB interaction not demonstrated","Single lab, pharmacological only"]},{"year":2013,"claim":"Demonstrated cell-autonomous ERβ requirement in oligodendrocytes for agonist-driven remyelination via PI3K/Akt/mTOR.","evidence":"Oligodendrocyte-specific conditional ERβ knockout in EAE with electrophysiology, immunostaining, and pathway Western blots","pmids":["24191028"],"confidence":"High","gaps":["Direct transcriptional targets in oligodendrocytes not defined","Whether effect is genomic or non-genomic unclear"]},{"year":2014,"claim":"Separated ERβ-specific circadian effects from ERα, showing ERβ activation reshapes locomotor activity distribution and phase responses.","evidence":"Selective agonists (PPT vs DPN) in ovariectomized mice with wheel-running and phase-response analysis","pmids":["24735329"],"confidence":"Medium","gaps":["Brain locus and target genes unidentified","Single lab pharmacological dissection"]},{"year":2016,"claim":"Provided human genetic proof that ERβ loss causes unopposed ERα signaling and tumorigenic proliferation, including de-repression of the RET promoter.","evidence":"Exome sequencing of a c.948delT frameshift with ERE/RET reporter, proliferation assays, and tumor immunostaining","pmids":["26945007"],"confidence":"High","gaps":["Single patient/mutation","Full spectrum of de-repressed targets not catalogued"]},{"year":2018,"claim":"Established ERβ's DNA-binding transcriptional activity as indispensable for ovulation and identified Kiss1 as a direct granulosa-cell target activated via promoter/enhancer EREs and gonadotropin-driven ERK phosphorylation.","evidence":"Esr2-null and DBD-mutant rats, granulosa-cell RNA-seq, ChIP, ERE-mutagenesis reporter assays, and kinase assays","pmids":["29580824","30277501"],"confidence":"High","gaps":["Functional hierarchy among the 1,696 DEGs unresolved","Role of ERβ phosphorylation site mutants not directly tested"]},{"year":2017,"claim":"Defined cardioprotective mechanisms by which E2/ERβ limits hypertrophy through Ca²⁺-calcineurin inhibition and limits apoptosis via PI3K/Akt/MDM2-mediated calcineurin degradation.","evidence":"ERβ overexpression in H9c2 cardiomyoblasts with pharmacological epistasis (CsA, BAPTA) and Western blots","pmids":["28863192","28441761"],"confidence":"High","gaps":["Genomic vs non-genomic contribution not separated","In vivo cardiac validation absent","Apoptosis arm single lab/single method"]},{"year":2020,"claim":"Defined ERβ as a transcription-dependent gatekeeper of the primordial follicle reserve, suppressing AKT/ERK/mTOR follicle activation, an effect specific to ERβ and not ERα.","evidence":"Esr2-null and DBD-mutant rats, ERβ agonist/antagonist (DPN/PHTPP), follicle counting, hormone measurement, and pathway Western blots; CRISPR full-gene-deletion mouse confirming sex-specific reproductive requirement","pmids":["32141511","32703416"],"confidence":"High","gaps":["Direct intrafollicular target genes controlling activation unconfirmed","Cell-of-origin (granulosa vs oocyte) of the signal unresolved"]},{"year":2024,"claim":"Extended ERβ as a transcriptional regulator into neural and joint contexts, repressing miR-10a to control BDNF/synaptic plasticity and acting via an LXA4/ESR2/LPAR3/Nrf2 axis to inhibit ferroptosis.","evidence":"Postpartum depression mouse models, primary neurons, luciferase reporters; KOA rat models with LPAR3 gain/loss and PHTPP antagonism","pmids":["39588356","38754271"],"confidence":"Medium","gaps":["Direct ERβ binding to miR-10a and LPAR3 loci not shown","Single lab for each axis","Causal hierarchy within multi-node pathways inferred"]},{"year":null,"claim":"How ERβ's genomic (ERE/Sp1/AP-1 binding) and non-genomic (p38, PI3K/Akt) activities are integrated within a given cell to specify antiproliferative, pro-apoptotic, or protective outcomes remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking conformation, dimer composition, and signaling output","Tissue-specific coregulator complements largely uncatalogued","Endogenous direct target gene atlas incomplete outside ovary"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,8,11,14,17,18,23]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,8,11,17,18]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[6,15,16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,4,7,11]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,4,8]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[8,11,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,15,16]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,8,11,17,18]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[17,18,19,20]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,16,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,21]}],"complexes":[],"partners":["ESR1","CBP/P300"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q92731","full_name":"Estrogen receptor beta","aliases":["Nuclear receptor subfamily 3 group A member 2"],"length_aa":530,"mass_kda":59.2,"function":"Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560) Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q92731/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ESR2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ESR2","total_profiled":1310},"omim":[{"mim_id":"618819","title":"PBX HOMEOBOX-INTERACTING PROTEIN 1; PBXIP1","url":"https://www.omim.org/entry/618819"},{"mim_id":"618187","title":"OVARIAN DYSGENESIS 8; ODG8","url":"https://www.omim.org/entry/618187"},{"mim_id":"617856","title":"THYMOCYTE SELECTION-ASSOCIATED PROTEIN FAMILY, MEMBER 2; THEMIS2","url":"https://www.omim.org/entry/617856"},{"mim_id":"617639","title":"DEAFNESS, AUTOSOMAL RECESSIVE 107; DFNB107","url":"https://www.omim.org/entry/617639"},{"mim_id":"616825","title":"NUCLEAR RECEPTOR COACTIVATOR 5; NCOA5","url":"https://www.omim.org/entry/616825"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":6.5},{"tissue":"ovary","ntpm":6.2},{"tissue":"testis","ntpm":5.6}],"url":"https://www.proteinatlas.org/search/ESR2"},"hgnc":{"alias_symbol":["NR3A2","Erb","ER-beta"],"prev_symbol":[]},"alphafold":{"accession":"Q92731","domains":[{"cath_id":"3.30.50.10","chopping":"157-211","consensus_level":"high","plddt":93.872,"start":157,"end":211},{"cath_id":"1.10.565.10","chopping":"264-410_418-503","consensus_level":"high","plddt":91.5539,"start":264,"end":503}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92731","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92731-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92731-F1-predicted_aligned_error_v6.png","plddt_mean":69.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ESR2","jax_strain_url":"https://www.jax.org/strain/search?query=ESR2"},"sequence":{"accession":"Q92731","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92731.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92731/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92731"}},"corpus_meta":[{"pmid":"3754034","id":"PMC_3754034","title":"Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3754034","citation_count":2086,"is_preprint":false},{"pmid":"8769313","id":"PMC_8769313","title":"ER beta: identification and characterization of a novel human estrogen receptor.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8769313","citation_count":1839,"is_preprint":false},{"pmid":"3003577","id":"PMC_3003577","title":"Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3003577","citation_count":1254,"is_preprint":false},{"pmid":"22460952","id":"PMC_22460952","title":"Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22460952","citation_count":878,"is_preprint":false},{"pmid":"22460951","id":"PMC_22460951","title":"Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22460951","citation_count":684,"is_preprint":false},{"pmid":"14993442","id":"PMC_14993442","title":"Estrogen signaling: a subtle balance between ER alpha and ER beta.","date":"2003","source":"Molecular interventions","url":"https://pubmed.ncbi.nlm.nih.gov/14993442","citation_count":572,"is_preprint":false},{"pmid":"24577401","id":"PMC_24577401","title":"REV-ERB and ROR nuclear receptors as drug targets.","date":"2014","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/24577401","citation_count":473,"is_preprint":false},{"pmid":"10823946","id":"PMC_10823946","title":"Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10823946","citation_count":397,"is_preprint":false},{"pmid":"10097152","id":"PMC_10097152","title":"Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10097152","citation_count":366,"is_preprint":false},{"pmid":"11517191","id":"PMC_11517191","title":"ER beta inhibits proliferation and invasion of breast cancer cells.","date":"2001","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11517191","citation_count":340,"is_preprint":false},{"pmid":"16938840","id":"PMC_16938840","title":"Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16938840","citation_count":313,"is_preprint":false},{"pmid":"9379111","id":"PMC_9379111","title":"Expression of oestrogen receptor beta (ER beta) in multiple rat tissues visualised by immunohistochemistry.","date":"1997","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9379111","citation_count":270,"is_preprint":false},{"pmid":"11355950","id":"PMC_11355950","title":"Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma.","date":"2001","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11355950","citation_count":257,"is_preprint":false},{"pmid":"10396301","id":"PMC_10396301","title":"HER-2/neu (c-erb-B2) gene and protein in breast cancer.","date":"1999","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10396301","citation_count":231,"is_preprint":false},{"pmid":"15389627","id":"PMC_15389627","title":"Survival versus apoptotic 17beta-estradiol effect: role of ER alpha and ER beta activated non-genomic signaling.","date":"2005","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15389627","citation_count":176,"is_preprint":false},{"pmid":"19696364","id":"PMC_19696364","title":"Rev-erb-alpha: an integrator of circadian rhythms and metabolism.","date":"2009","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/19696364","citation_count":144,"is_preprint":false},{"pmid":"31127047","id":"PMC_31127047","title":"SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31127047","citation_count":141,"is_preprint":false},{"pmid":"10381820","id":"PMC_10381820","title":"Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells.","date":"1999","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/10381820","citation_count":141,"is_preprint":false},{"pmid":"22161825","id":"PMC_22161825","title":"The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology.","date":"2011","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22161825","citation_count":136,"is_preprint":false},{"pmid":"12037685","id":"PMC_12037685","title":"Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12037685","citation_count":134,"is_preprint":false},{"pmid":"15355905","id":"PMC_15355905","title":"Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15355905","citation_count":134,"is_preprint":false},{"pmid":"21479263","id":"PMC_21479263","title":"Direct regulation of CLOCK expression by REV-ERB.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21479263","citation_count":130,"is_preprint":false},{"pmid":"16024756","id":"PMC_16024756","title":"Estrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-estradiol.","date":"2005","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16024756","citation_count":129,"is_preprint":false},{"pmid":"14762170","id":"PMC_14762170","title":"Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14762170","citation_count":114,"is_preprint":false},{"pmid":"19001520","id":"PMC_19001520","title":"Estrogen receptor (ER) beta regulates ERalpha expression in stromal cells derived from ovarian endometriosis.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19001520","citation_count":114,"is_preprint":false},{"pmid":"20427485","id":"PMC_20427485","title":"Regulation of adipogenesis by natural and synthetic REV-ERB ligands.","date":"2010","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20427485","citation_count":111,"is_preprint":false},{"pmid":"15863464","id":"PMC_15863464","title":"Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle.","date":"2005","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15863464","citation_count":106,"is_preprint":false},{"pmid":"33430527","id":"PMC_33430527","title":"Estrogen and Glycemic Homeostasis: The Fundamental Role of Nuclear Estrogen Receptors ESR1/ESR2 in Glucose Transporter GLUT4 Regulation.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33430527","citation_count":85,"is_preprint":false},{"pmid":"15477868","id":"PMC_15477868","title":"Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer.","date":"2004","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15477868","citation_count":83,"is_preprint":false},{"pmid":"17765229","id":"PMC_17765229","title":"Rev-erb alpha gives a time cue to metabolism.","date":"2007","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/17765229","citation_count":83,"is_preprint":false},{"pmid":"9829551","id":"PMC_9829551","title":"Oestrogen receptor beta (ER beta).","date":"1998","source":"Reviews of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/9829551","citation_count":81,"is_preprint":false},{"pmid":"29232411","id":"PMC_29232411","title":"Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29232411","citation_count":79,"is_preprint":false},{"pmid":"35034472","id":"PMC_35034472","title":"Myocardial Rev-erb-Mediated Diurnal Metabolic Rhythm and Obesity Paradox.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/35034472","citation_count":78,"is_preprint":false},{"pmid":"15582272","id":"PMC_15582272","title":"Estrogen and the brain: beyond ER-alpha and ER-beta.","date":"2004","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/15582272","citation_count":72,"is_preprint":false},{"pmid":"29580824","id":"PMC_29580824","title":"ESR2 regulates granulosa cell genes essential for follicle maturation and ovulation.","date":"2018","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29580824","citation_count":71,"is_preprint":false},{"pmid":"33762728","id":"PMC_33762728","title":"REV-ERB in GABAergic neurons controls diurnal hepatic insulin sensitivity.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33762728","citation_count":68,"is_preprint":false},{"pmid":"12398995","id":"PMC_12398995","title":"Human oestrogen receptors: differential expression of ER alpha and beta and the identification of ER beta variants.","date":"2002","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/12398995","citation_count":67,"is_preprint":false},{"pmid":"24191028","id":"PMC_24191028","title":"Estrogen receptor (ER) β expression in oligodendrocytes is required for attenuation of clinical disease by an ERβ ligand.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24191028","citation_count":67,"is_preprint":false},{"pmid":"18996135","id":"PMC_18996135","title":"Effect of ER-beta gene disruption on estrogenic regulation of anxiety in female mice.","date":"2008","source":"Physiology & behavior","url":"https://pubmed.ncbi.nlm.nih.gov/18996135","citation_count":61,"is_preprint":false},{"pmid":"35304506","id":"PMC_35304506","title":"Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35304506","citation_count":59,"is_preprint":false},{"pmid":"11496329","id":"PMC_11496329","title":"Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas.","date":"2001","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/11496329","citation_count":58,"is_preprint":false},{"pmid":"16261413","id":"PMC_16261413","title":"Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer.","date":"2005","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/16261413","citation_count":57,"is_preprint":false},{"pmid":"12021204","id":"PMC_12021204","title":"Expression of ER-alpha and ER-beta in the hamster ovary: differential regulation by gonadotropins and ovarian steroid hormones.","date":"2002","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12021204","citation_count":56,"is_preprint":false},{"pmid":"24352099","id":"PMC_24352099","title":"Sex-specific Esr2 mRNA expression in the rat hypothalamus and amygdala is altered by neonatal bisphenol A exposure.","date":"2014","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24352099","citation_count":50,"is_preprint":false},{"pmid":"39588356","id":"PMC_39588356","title":"Deciphering and Targeting the ESR2-miR-10a-5p-BDNF Axis in the Prefrontal Cortex: Advancing Postpartum Depression Understanding and Therapeutics.","date":"2024","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/39588356","citation_count":49,"is_preprint":false},{"pmid":"29085009","id":"PMC_29085009","title":"Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29085009","citation_count":47,"is_preprint":false},{"pmid":"18375409","id":"PMC_18375409","title":"Genetic polymorphisms of ESR1 and ESR2 that may influence estrogen activity and the risk of hypospadias.","date":"2008","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18375409","citation_count":45,"is_preprint":false},{"pmid":"24735329","id":"PMC_24735329","title":"ESR1 and ESR2 differentially regulate daily and circadian activity rhythms in female mice.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24735329","citation_count":44,"is_preprint":false},{"pmid":"15291741","id":"PMC_15291741","title":"The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts.","date":"2004","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15291741","citation_count":44,"is_preprint":false},{"pmid":"18093886","id":"PMC_18093886","title":"ER-beta expression in large bowel adenomas: implications in colon carcinogenesis.","date":"2008","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/18093886","citation_count":43,"is_preprint":false},{"pmid":"2904292","id":"PMC_2904292","title":"Hypomethylation of ornithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia.","date":"1988","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2904292","citation_count":42,"is_preprint":false},{"pmid":"12109857","id":"PMC_12109857","title":"Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions.","date":"2002","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12109857","citation_count":41,"is_preprint":false},{"pmid":"9458291","id":"PMC_9458291","title":"c-myc, c-erb-B2, nm23 and p53 expression in human endometriosis.","date":"1998","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/9458291","citation_count":40,"is_preprint":false},{"pmid":"38754271","id":"PMC_38754271","title":"Lipoxin A4 ameliorates knee osteoarthritis progression in rats by antagonizing ferroptosis through activation of the ESR2/LPAR3/Nrf2 axis in synovial fibroblast-like synoviocytes.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38754271","citation_count":39,"is_preprint":false},{"pmid":"20390341","id":"PMC_20390341","title":"A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk.","date":"2011","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/20390341","citation_count":39,"is_preprint":false},{"pmid":"32764708","id":"PMC_32764708","title":"Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32764708","citation_count":39,"is_preprint":false},{"pmid":"32141511","id":"PMC_32141511","title":"A Gatekeeping Role of ESR2 to Maintain the Primordial Follicle Reserve.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32141511","citation_count":38,"is_preprint":false},{"pmid":"29401617","id":"PMC_29401617","title":"REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29401617","citation_count":38,"is_preprint":false},{"pmid":"11752866","id":"PMC_11752866","title":"Expression of estrogen receptor (ER-alpha and ER-beta) mRNA in human prostate cancer.","date":"2001","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/11752866","citation_count":37,"is_preprint":false},{"pmid":"24173768","id":"PMC_24173768","title":"REV-ERB-ALPHA circadian gene variant associates with obesity in two independent populations: Mediterranean and North American.","date":"2013","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/24173768","citation_count":37,"is_preprint":false},{"pmid":"29215066","id":"PMC_29215066","title":"Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29215066","citation_count":37,"is_preprint":false},{"pmid":"3464613","id":"PMC_3464613","title":"Amplification of RNA and DNA specific for erb B in unbalanced 1;7 chromosomal translocation associated with myelodysplastic syndrome.","date":"1986","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3464613","citation_count":36,"is_preprint":false},{"pmid":"25526766","id":"PMC_25526766","title":"ESR1 and ESR2 gene polymorphisms are associated with human reproduction outcomes in Brazilian women.","date":"2014","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/25526766","citation_count":34,"is_preprint":false},{"pmid":"21658000","id":"PMC_21658000","title":"ESR1, ESR2 and FSH receptor gene polymorphisms in combination: a useful genetic tool for the prediction of poor responders.","date":"2012","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/21658000","citation_count":33,"is_preprint":false},{"pmid":"15161628","id":"PMC_15161628","title":"Estrogen receptor-1 (Esr1) and -2 (Esr2) regulate the severity of clinical experimental allergic encephalomyelitis in male mice.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15161628","citation_count":32,"is_preprint":false},{"pmid":"18765668","id":"PMC_18765668","title":"Estrogen receptor (ER) beta or p53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18765668","citation_count":30,"is_preprint":false},{"pmid":"36414641","id":"PMC_36414641","title":"Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36414641","citation_count":30,"is_preprint":false},{"pmid":"18569528","id":"PMC_18569528","title":"Estrogen receptors alpha (ESR1) and beta (ESR2) are expressed in circulating human lymphocytes.","date":"2008","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/18569528","citation_count":30,"is_preprint":false},{"pmid":"28213272","id":"PMC_28213272","title":"Rev-erb regulation of cholesterologenesis.","date":"2017","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28213272","citation_count":29,"is_preprint":false},{"pmid":"28702326","id":"PMC_28702326","title":"Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome.","date":"2017","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28702326","citation_count":29,"is_preprint":false},{"pmid":"15280642","id":"PMC_15280642","title":"Estrogen receptor beta (ESR2 ) polymorphisms and endometrial cancer (United States).","date":"2004","source":"Cancer causes & control : CCC","url":"https://pubmed.ncbi.nlm.nih.gov/15280642","citation_count":28,"is_preprint":false},{"pmid":"26945007","id":"PMC_26945007","title":"Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26945007","citation_count":27,"is_preprint":false},{"pmid":"32738989","id":"PMC_32738989","title":"The transcriptional repressor REV-ERB as a novel target for disease.","date":"2020","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/32738989","citation_count":26,"is_preprint":false},{"pmid":"31575907","id":"PMC_31575907","title":"Unraveling FATP1, regulated by ER-β, as a targeted breast cancer innovative therapy.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31575907","citation_count":26,"is_preprint":false},{"pmid":"30277501","id":"PMC_30277501","title":"ESR2 Is Essential for Gonadotropin-Induced Kiss1 Expression in Granulosa Cells.","date":"2018","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30277501","citation_count":25,"is_preprint":false},{"pmid":"21174621","id":"PMC_21174621","title":"The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.","date":"2011","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/21174621","citation_count":24,"is_preprint":false},{"pmid":"19447495","id":"PMC_19447495","title":"ERB-041, a selective ER beta agonist, inhibits iNOS production in LPS-activated peritoneal macrophages of endometriosis via suppression of NF-kappaB activation.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19447495","citation_count":24,"is_preprint":false},{"pmid":"18424193","id":"PMC_18424193","title":"Development of ER-alpha and ER-beta expression in the developing ovine brain and pituitary.","date":"2008","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/18424193","citation_count":24,"is_preprint":false},{"pmid":"27840152","id":"PMC_27840152","title":"Rev-erb agonist and TGF-β similarly affect autophagy but differentially regulate hepatic stellate cell fibrogenic phenotype.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27840152","citation_count":23,"is_preprint":false},{"pmid":"24647635","id":"PMC_24647635","title":"Association of polymorphisms in estrogen receptors (ESR1 and ESR2) with male infertility: a meta-analysis and systematic review.","date":"2014","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24647635","citation_count":22,"is_preprint":false},{"pmid":"32169631","id":"PMC_32169631","title":"Association of estrogen receptor gene variants (ESR1 and ESR2) with polycystic ovary syndrome in Tunisia.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32169631","citation_count":21,"is_preprint":false},{"pmid":"29664547","id":"PMC_29664547","title":"HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in infertile women with endometriosis.","date":"2018","source":"Ginekologia polska","url":"https://pubmed.ncbi.nlm.nih.gov/29664547","citation_count":21,"is_preprint":false},{"pmid":"24859835","id":"PMC_24859835","title":"The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24859835","citation_count":21,"is_preprint":false},{"pmid":"7668939","id":"PMC_7668939","title":"Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis.","date":"1995","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7668939","citation_count":21,"is_preprint":false},{"pmid":"29535531","id":"PMC_29535531","title":"Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29535531","citation_count":20,"is_preprint":false},{"pmid":"22212297","id":"PMC_22212297","title":"Investigation on association and expression of ESR2 as a candidate gene for boar sperm quality and fertility.","date":"2011","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/22212297","citation_count":20,"is_preprint":false},{"pmid":"33339862","id":"PMC_33339862","title":"Methylation of estrogen receptor 2 (ESR2) in deep paravertebral muscles and its association with idiopathic scoliosis.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33339862","citation_count":19,"is_preprint":false},{"pmid":"20340172","id":"PMC_20340172","title":"ER-β mediates 17β-estradiol attenuation of HIV-1 Tat-induced apoptotic signaling.","date":"2010","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20340172","citation_count":19,"is_preprint":false},{"pmid":"34207568","id":"PMC_34207568","title":"Altered Expression of ESR1, ESR2, PELP1 and c-SRC Genes Is Associated with Ovarian Cancer Manifestation.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34207568","citation_count":18,"is_preprint":false},{"pmid":"28863192","id":"PMC_28863192","title":"E2/ER β inhibit ISO-induced cardiac cellular hypertrophy by suppressing Ca2+-calcineurin signaling.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28863192","citation_count":18,"is_preprint":false},{"pmid":"28441761","id":"PMC_28441761","title":"E2/ER β Enhances Calcineurin Protein Degradation and PI3K/Akt/MDM2 Signal Transduction to Inhibit ISO-Induced Myocardial Cell Apoptosis.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28441761","citation_count":18,"is_preprint":false},{"pmid":"32544536","id":"PMC_32544536","title":"Estrogen receptor (ESR1 and ESR2)-mediated activation of eNOS-NO-cGMP pathway facilitates high altitude acclimatization.","date":"2020","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32544536","citation_count":17,"is_preprint":false},{"pmid":"19927160","id":"PMC_19927160","title":"Association between ESR1 and ESR2 gene polymorphisms and hyperlipidemia in Chinese Han postmenopausal women.","date":"2009","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19927160","citation_count":17,"is_preprint":false},{"pmid":"14973391","id":"PMC_14973391","title":"The normal and malignant mammary gland: a fresh look with ER beta onboard.","date":"2000","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/14973391","citation_count":17,"is_preprint":false},{"pmid":"31969267","id":"PMC_31969267","title":"Depressive behavior induced by nonylphenol and its effect on the expression of ER-α and ER-β in nerve cells of rats.","date":"2019","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31969267","citation_count":17,"is_preprint":false},{"pmid":"32150902","id":"PMC_32150902","title":"Interaction of Coumarin Phytoestrogens with ERα and ERβ: A Molecular Dynamics Simulation Study.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32150902","citation_count":16,"is_preprint":false},{"pmid":"19682428","id":"PMC_19682428","title":"Rev-erb beta regulates the Srebp-1c promoter and mRNA expression in skeletal muscle cells.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19682428","citation_count":16,"is_preprint":false},{"pmid":"32703416","id":"PMC_32703416","title":"Generation of an all-exon Esr2 deleted mouse line: Effects on fertility.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32703416","citation_count":16,"is_preprint":false},{"pmid":"26147849","id":"PMC_26147849","title":"Changes in Estrogen Receptor ERβ (ESR2) Expression without Changes in the Estradiol Levels in the Prostate of Aging Rats.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26147849","citation_count":16,"is_preprint":false},{"pmid":"34710471","id":"PMC_34710471","title":"Transcriptional regulation of CYP19A1 expression in chickens: ESR1, ESR2 and NR5A2 form a functional network.","date":"2021","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34710471","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51556,"output_tokens":7220,"usd":0.131484,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16837,"output_tokens":5888,"usd":0.115693,"stage2_stop_reason":"end_turn"},"total_usd":0.247177,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"ESR2 (ERβ) was cloned as a novel estrogen receptor with high conservation in the DNA-binding domain (96%) and ligand-binding domain (58%) relative to ERα. Transient transfection of ESR2 with an ERE-based reporter in CHO cells demonstrated 17β-estradiol-induced transactivation, and ICI-164384 (an ERα antagonist) also acts as a potent antagonist for ESR2. ESR2 shows lower transactivation levels than ERα under equivalent conditions.\",\n      \"method\": \"Degenerate PCR cloning, sequence homology analysis, transient transfection reporter assay, pharmacological antagonism\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro transactivation assay with reporter gene and pharmacological characterization; foundational cloning paper replicated widely\",\n      \"pmids\": [\"8769313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ERβ and ERα adopt distinct ligand-dependent conformational changes when bound to estradiol versus 4-OH tamoxifen, as revealed by differential peptide binding surfaces on each receptor complex. These conformation-specific peptides can discriminate between ERα and ERβ ligand complexes, providing a structural basis for isoform- and ligand-specific biological activities.\",\n      \"method\": \"Affinity selection of peptides to probe receptor conformation (peptide phage display / affinity selection) on apo-ER and ligand-bound ER complexes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct structural/conformational probing using peptide affinity selection with multiple ligands and both receptor isoforms\",\n      \"pmids\": [\"10097152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ERβ (ESR2) modulates ERα activity in the uterus: BERKO (ERβ knockout) mice exhibit elevated progesterone receptor, increased Ki-67, and exaggerated E2 responses (uterine enlargement, elevated C3, IL-1β, VEGF, IGF-1), demonstrating that ERβ has an antiproliferative, modulatory function opposing ERα-mediated actions.\",\n      \"method\": \"ERβ knockout mouse model (BERKO), immunohistochemistry, protein quantification, hormonal challenge experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in vivo with multiple orthogonal phenotypic readouts; replicated concept across labs\",\n      \"pmids\": [\"10823946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERβ (ESR2), when expressed via adenoviral vector in ER-negative MDA-MB-231 breast cancer cells, localizes to the nucleus, transactivates ERE-reporter constructs in the presence of E2, induces pS2, TGFα, and p21 expression, inhibits cell proliferation in a ligand-independent manner, and decreases cell motility and invasion. Unlike ERα, ERβ does not regulate c-myc expression.\",\n      \"method\": \"Adenoviral vector-mediated expression, RT-PCR, Western blot, immunocytochemistry, ERE-reporter transactivation assay, proliferation assay, invasion/motility assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays in a clean ER-null cell system with defined readouts\",\n      \"pmids\": [\"11517191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ERα and ERβ form functional heterodimers when coexpressed; ERβ exhibits inhibitory action on ERα-mediated gene expression in multiple cell-type and promoter contexts, opposing ERα transcriptional activity.\",\n      \"method\": \"Transient transfection, reporter gene assays, coexpression studies (review summarizing experimental evidence)\",\n      \"journal\": \"Molecular interventions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — review article summarizing experimental data from multiple labs, but this paper itself is a review; underlying experiments are multiply replicated\",\n      \"pmids\": [\"14993442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Both ERα and ERβ can independently mediate E2-induced proliferation in mammary gland epithelial cells. ERβ facilitates the return of ERα to the nucleus after E2-induced nuclear export, thereby restoring E2 responsiveness. After E2 treatment, ERα is lost from nuclei of epithelial cells within 4 h; in ERβ-knockout mice, re-entry of ERα is delayed by an additional 24 h. Tamoxifen treatment retains ERα but loses ERβ from the nucleus.\",\n      \"method\": \"BrdUrd incorporation assay, immunohistochemistry with subtype-specific antibodies, ERβ-knockout (ERβ−/−) mouse model, hormonal challenge\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model combined with multiple imaging and proliferation readouts in vivo\",\n      \"pmids\": [\"14762170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The E2-ERβ complex rapidly and persistently activates p38/MAPK, leading to caspase-3 activation and PARP cleavage, driving cells into apoptosis. In contrast to E2-ERα, the E2-ERβ complex does not activate ERK/MAPK or PI3K/AKT survival pathways. These non-genomic signaling differences were demonstrated in cells containing endogenous (HepG2, DLD1) or transfected (HeLa) ERβ or ERα.\",\n      \"method\": \"Transient transfection, kinase activation assays (ERK/MAPK, p38/MAPK, PI3K/AKT), caspase-3 activity assay, PARP cleavage, cell growth/apoptosis measurements in multiple cell lines\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal signaling assays across several cell lines with endogenous and exogenous receptor\",\n      \"pmids\": [\"15389627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ESR2 isoforms β2, β4, and β5 lack a functional helix 12 (required for coactivator binding); they cannot form homodimers and have no intrinsic transactivation activity. However, they heterodimerize with ERβ1 and enhance its transactivation in a ligand-dependent manner. ERβ1 is the obligatory partner in ERβ dimers; a single functional helix 12 per dimer is sufficient for gene transactivation. ERβ1 preferentially forms heterodimers with other isoforms under estrogen but not phytoestrogen stimulation.\",\n      \"method\": \"Molecular modeling, transient transfection reporter assays, dimerization assays (co-immunoprecipitation), isoform-specific expression from prostate cell line\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — molecular modeling with functional validation by reporter assay and dimerization experiments, multiple isoforms tested\",\n      \"pmids\": [\"16938840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERβ (ESR2) suppresses ERα gene expression in endometriotic stromal cells by binding to non-classical AP-1 and Sp1 motifs in ERα promoters A and C, and to a classic ERE in promoter B (shown by ChIP). ERβ knockdown increases ERα mRNA and protein; ERβ overexpression decreases ERα mRNA and protein. ERβ also regulates cell cycle progression in endometriotic stromal cells.\",\n      \"method\": \"siRNA knockdown, overexpression, RT-PCR, Western blot, chromatin immunoprecipitation (ChIP), promoter analysis\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct ERβ binding to ERα promoters, supported by reciprocal gain/loss-of-function experiments\",\n      \"pmids\": [\"19001520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERβ (ESR2) mediates anxiety-regulation: lower-dose E2 treatment exerts anxiolytic effects partially through ERβ in female mice, as ERβ-knockout (betaERKO) mice show attenuated anxiolytic responses in the social investigation test compared to wild-type, while high-dose E2 anxiogenic effects are ERβ-independent.\",\n      \"method\": \"ERβ-knockout mouse model, light-dark transition test, elevated plus-maze test, social investigation test, estradiol dose-response\",\n      \"journal\": \"Physiology & behavior\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic KO with behavioral readout, single lab, partial effect only at low doses\",\n      \"pmids\": [\"18996135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ESR2 loss-of-function in male mice (Esr2−/−) does not alter EAE disease severity, while heterozygosity (Esr2+/−) increases disease severity with earlier onset (heterotic effect). Bone marrow chimera experiments established that the heterotic effect at Esr2 in regulating EAE severity is a function of the non-hematopoietic compartment. ESR2 genotype-dependently regulates IL-6 and TNF-α cytokine secretion.\",\n      \"method\": \"ERβ-knockout and heterozygous mouse models, EAE immunization, reciprocal bone marrow chimeras, cytokine assays (proliferation, IL-2, IFN-γ, IL-6, TNF-α, MCP-1)\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via reciprocal bone marrow chimeras with defined cytokine readouts\",\n      \"pmids\": [\"15161628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERβ (ESR2) attenuates ERα-mediated transcriptional activation of the BRCA2 promoter: ERβ interacts with ERα and CBP/p300, forming a weak activating complex that competes with the ERα-CBP/p300-p68/p72-MyoD complex for Sp1 binding sites on the BRCA2 promoter, reducing histone acetylation and BRCA2 transcription.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, reporter gene assay, site-directed mutagenesis of Sp1 sites, Western blot for histone acetylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP, and reporter assays with mechanistic dissection of complex composition\",\n      \"pmids\": [\"18765668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERβ (ESR2) expression specifically in oligodendrocytes (OLs) is required for the neuroprotective and pro-myelination effects of the ERβ agonist DPN in EAE mice. Conditional deletion of ERβ in OLs prevented DPN-induced decrease in EAE clinical disease, blocked DPN-induced attenuation of demyelination, impaired axon conduction recovery, and abolished PI3K/Akt/mTOR pathway activation in OLs, while BDNF upregulation by DPN was preserved.\",\n      \"method\": \"Conditional Cre-loxP knockout of ESR2 in oligodendrocytes, EAE model, electrophysiology (axon conduction), immunostaining, Western blot (PI3K/Akt/mTOR), ELISA (BDNF)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with multiple orthogonal mechanistic readouts\",\n      \"pmids\": [\"24191028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ESR2 activation (using the selective agonist diarylpropionitrile, DPN) modifies the distribution of daily locomotor activity, delays acrophase of wheel running, and advances the time of activity onset in ovariectomized female mice; DPN also attenuates photic phase-shifting in the early subjective night. These effects are distinct from ESR1-mediated effects on total activity and amplitude.\",\n      \"method\": \"Ovariectomy, selective ESR1/ESR2 agonist administration (PPT vs. DPN), wheel-running activity measurement, free-running period analysis, light-pulse phase-response curve\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection using selective agonists with quantitative circadian readouts, single lab\",\n      \"pmids\": [\"24735329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A germline ESR2 frameshift mutation (c.948delT) causes loss of ERβ expression and results in unopposed ERα-mediated transcriptional activation. In vitro, this ESR2 mutation leads to increased cellular proliferation, activation of ERE-containing reporters, and increased RET promoter-driven expression (the RET promoter contains three EREs). ERβ normally represses ERα-mediated activation of the RET promoter.\",\n      \"method\": \"Exome resequencing, in vitro reporter assay (ERE and RET promoter), cell proliferation assay, immunostaining for RET protein in tumor tissue\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional mutation analysis with in vitro reporter assay and in vivo tumor immunostaining confirming mechanism\",\n      \"pmids\": [\"26945007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"E2/ERβ suppresses isoproterenol (ISO)-induced cardiomyocyte hypertrophy by inhibiting Ca2+-calcineurin signaling: ERβ overexpression and/or E2 treatment blocked ISO-induced upregulation of ANP, BNP, p-CaMKII, calcineurin, p-GATA4, and NFATc3, and inhibited NFATc3 nuclear translocation. The calcineurin inhibitor CsA confirmed calcineurin as the key mediator; calcium chelation (BAPTA) blocked the anti-hypertrophic effect, establishing that ERβ acts by reducing Ca2+ influx and thereby inhibiting calcineurin to activate I-1 protein, suppress PP1, and enhance PLB phosphorylation to restore SR Ca2+ cycling.\",\n      \"method\": \"ERβ overexpression in H9c2 cardiomyoblasts, Western blot, immunofluorescence (NFATc3 translocation), pharmacological inhibitors (CsA, BAPTA), ISO-induced hypertrophy model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain-of-function overexpression with multiple pharmacological epistasis experiments and mechanistic pathway dissection\",\n      \"pmids\": [\"28863192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"E2/ERβ inhibits isoproterenol-induced myocardial cell apoptosis by promoting calcineurin protein degradation through activation of the PI3K/Akt/MDM2 signaling pathway, suppressing cytochrome c release and downstream apoptotic markers.\",\n      \"method\": \"ERβ overexpression in H9c2 cells, ISO-induced apoptosis model, Western blot (calcineurin, PI3K/Akt/MDM2, cytochrome c, apoptosis markers)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function in cell model with defined signaling pathway, single lab, single method type\",\n      \"pmids\": [\"28441761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ESR2 regulates granulosa cell genes essential for follicle maturation and ovulation. Both null and DNA-binding domain (DBD) mutant ESR2 rats fail to ovulate, demonstrating that ESR2 transcriptional activity (via DNA binding) is indispensable for ovulation. RNA-seq identified 1,696 differentially expressed genes in Esr2-mutant granulosa cells including steroidogenesis, follicle maturation, and ovulation pathways; Kiss1 was identified as an ESR2-regulated gene in granulosa cells.\",\n      \"method\": \"Esr2-null and DBD-mutant rat models, exogenous gonadotropin stimulation, granulosa cell isolation, RNA-sequencing, molecular pathway analysis\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two distinct genetic models (null and DBD mutant) with genome-wide transcriptomic readout establishing canonical transcriptional mechanism\",\n      \"pmids\": [\"29580824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ESR2 is required for gonadotropin-induced Kiss1 expression in granulosa cells. ESR2 binds directly to estrogen response elements (EREs) in the Kiss1 promoter and both upstream and downstream enhancers (shown by ChIP). ESR2 overexpression induces Kiss1 promoter activity, and ERE mutation abolishes this induction. Gonadotropins induce ERK2-mediated ESR2 phosphorylation, upregulate AP-1 factors (FOSL2, JUNB), which synergistically activate the Kiss1 promoter together with ESR2.\",\n      \"method\": \"ChIP, reporter gene/luciferase assay, ERE site-directed mutagenesis, ESR2 overexpression, kinase phosphorylation assays, Esr2-null rat model\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP demonstrating direct binding, reporter assay with mutagenesis, genetic KO confirmation, and signaling pathway dissection\",\n      \"pmids\": [\"30277501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ESR2 acts as a gatekeeper to maintain the primordial follicle reserve by suppressing follicle activation. Esr2-null (Esr2−/−) rats show increased activation of primordial follicles (not increased total follicle number), premature ovarian senescence, reduced serum AMH and estradiol. ESR2-specific antagonist (PHTPP) increases activated follicle counts; ESR2 agonist (DPN) decreases activation. ESR1 loss does not increase primordial follicle activation (ESR2-specific effect). ESR2 loss augments AKT, ERK, and mTOR pathway activation in both granulosa cells and oocytes, suggesting a direct intrafollicular regulatory mechanism via canonical transcriptional function (DNA-binding domain mutant also shows increased activation).\",\n      \"method\": \"Esr2-null and DBD-mutant rat models, selective agonist/antagonist treatment, follicle counting, hormone measurement (AMH, estradiol), Western blot (AKT, ERK, mTOR phosphorylation)\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two genetic models plus pharmacological manipulation, multiple orthogonal mechanistic readouts\",\n      \"pmids\": [\"32141511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ESR2 (ERβ) generates an all-exon deleted mouse (Esr2ΔE1-10). Female Esr2ΔE1-10 mice are subfertile at young age and become infertile/severely subfertile by ~6 months. Ovaries are smaller with very few corpora lutea (defect in ovulation), and estradiol levels are reduced at diestrus. Male Esr2ΔE1-10 mice are fertile, establishing that ERβ is required for female but not male reproductive function.\",\n      \"method\": \"CRISPR/Cas9 full-gene deletion, fertility tracking (litter number, litter size), ovarian histomorphology, hormone measurement (serum estradiol)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complete gene deletion model with sex-specific reproductive phenotype and hormonal mechanistic readout\",\n      \"pmids\": [\"32703416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ERβ agonist ERB-041 inhibits LPS-induced iNOS production in peritoneal macrophages of endometriosis by suppressing NF-κB nuclear translocation (preventing p65 nuclear accumulation), but does not act through the ERK pathway (ERK activity is not repressed by ER activation). Peritoneal macrophages from endometriosis patients express higher levels of ERβ relative to ERα.\",\n      \"method\": \"RT-PCR, immunoblot (ERα/ERβ expression, iNOS, p65, ERKs), pharmacological treatment with ERB-041 (ERβ agonist) and U0126 (ERK inhibitor), LPS stimulation\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological agonist with pathway-specific inhibitors and defined mechanistic readout, single lab\",\n      \"pmids\": [\"19447495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERβ (ER-β) regulates FATP1/SLC27A1 expression in breast cancer cells: treatment with estradiol plus the ERβ antagonist PHTPP blocked estradiol-induced FATP1/SLC27A1 upregulation, fatty acid uptake, and cell viability in four breast cancer cell lines, establishing ERβ as the receptor mediating these estrogen effects on fatty acid transport.\",\n      \"method\": \"Pharmacological ERβ antagonism (PHTPP), estradiol treatment, RT-qPCR/protein expression, fatty acid uptake assay, cell viability assay in 4 breast cancer cell lines\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection in multiple cell lines with multiple readouts, single lab\",\n      \"pmids\": [\"31575907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ESR2 acts as a negative transcription factor to down-regulate miR-10a transcription in the prefrontal cortex; miR-10a-5p in turn suppresses BDNF expression. This ESR2→miR-10a-5p→BDNF axis affects synaptic plasticity (synapse-related proteins SYP, SYN, PSD95 and glutamate receptor expression) and contributes to postpartum depressive-like behavior. Bioinformatics, in vivo mouse models, cell transfection, and primary neuron cultures were used to validate the pathway.\",\n      \"method\": \"Bioinformatics, in vivo behavioral studies (postpartum depression mouse model), cell transfection, primary neuron culture, stereotactic/intranasal antagomir delivery, Western blot (synaptic proteins), luciferase reporter\",\n      \"journal\": \"Research (Washington, D.C.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vivo and in vitro methods establishing transcriptional regulatory axis; single lab\",\n      \"pmids\": [\"39588356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ESR2 activation by LXA4 inhibits ferroptosis in fibroblast-like synoviocytes (FLSs) through the ESR2/LPAR3/Nrf2 axis: LXA4 upregulates ESR2, LPAR3, and GPX4 in FLSs. LPAR3 overexpression upregulates GPX4, Nrf2, and SOD1 while downregulating MMP13 and MMP3; LPAR3 knockdown reverses these changes. The ESR2 antagonist PHTPP partially reversed the beneficial effects of exercise on synovial and cartilage pathology in a rat KOA model.\",\n      \"method\": \"GSE29746 dataset analysis, synovial tissue sampling from KOA patients, LPAR3 overexpression/knockdown in vitro, rat MIA-induced KOA model, ESR2 antagonist (PHTPP) treatment, Western blot (GPX4, Nrf2, SOD1, MMPs)\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function for LPAR3 with defined molecular readouts, pharmacological ESR2 antagonism in vivo; single lab\",\n      \"pmids\": [\"38754271\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ESR2 (ERβ) is a ligand-activated nuclear receptor that, upon 17β-estradiol binding, transactivates ERE-containing target genes (including Kiss1, BRCA2, and others) through direct DNA binding requiring its DNA-binding domain and helix 12; it forms homodimers (with ERβ1 as obligatory partner) and heterodimers with ERα and other ERβ isoforms, generally opposing ERα-mediated transcriptional activation via competition at promoter binding sites; non-genomically, the E2-ERβ complex activates p38/MAPK to drive apoptosis while suppressing ERK/MAPK and PI3K/AKT survival signaling; in the ovary ESR2 is indispensable for follicular maturation, ovulation, and maintenance of the primordial follicle reserve via AKT/ERK/mTOR pathway suppression; in the myocardium ERβ limits hypertrophy and apoptosis by modulating Ca²⁺-calcineurin-PI3K/Akt/MDM2 signaling; in oligodendrocytes ERβ mediates pro-myelination neuroprotection via PI3K/Akt/mTOR; and in macrophages ERβ suppresses NF-κB nuclear translocation to reduce iNOS expression.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ESR2 (ERβ) is a ligand-activated nuclear receptor that, upon 17β-estradiol binding, transactivates ERE-containing target genes through a DNA-binding domain that is highly conserved with ERα, but with intrinsically lower transactivation potency [#0]. Distinct ligand-dependent conformational changes distinguish ERβ from ERα and underlie isoform-specific activity [#1]. A recurring theme across tissues is that ERβ acts as an antiproliferative modulator that opposes ERα: in the uterus ERβ restrains ERα-driven proliferative responses [#2], in ER-negative breast cancer cells reintroduced ERβ induces pS2, TGFα, and p21 while inhibiting proliferation, motility, and invasion [#3], and it directly attenuates ERα-mediated transcription by competing at promoter binding sites — repressing the BRCA2 promoter through an ERβ–CBP/p300 complex that displaces the activating ERα complex from Sp1 sites [#11], and binding AP-1, Sp1, and ERE motifs in the ERα promoter to suppress ERα expression itself [#8]. Loss of ERβ produces unopposed ERα signaling and increased proliferation, and a germline ESR2 frameshift mutation (c.948delT) abolishing ERβ expression de-represses the ERE-containing RET promoter [#14]. Receptor dimerization is constrained by isoform structure: ERβ2/β4/β5 isoforms lack a functional helix 12 and cannot homodimerize or transactivate alone, but heterodimerize with the obligatory ERβ1 partner to enhance its ligand-dependent activity [#7]. ERβ also signals non-genomically, with the E2–ERβ complex selectively activating p38/MAPK to drive caspase-3-dependent apoptosis while failing to engage the ERK and PI3K/AKT survival pathways activated by ERα [#6]. In the ovary ERβ is indispensable for follicular maturation and ovulation through its DNA-binding transcriptional activity, directly driving Kiss1 expression via promoter and enhancer EREs in granulosa cells [#17, #18], and it acts as a gatekeeper of the primordial follicle reserve by suppressing AKT/ERK/mTOR-dependent follicle activation [#19]. Beyond reproduction, ERβ limits cardiomyocyte hypertrophy and apoptosis by inhibiting Ca²⁺–calcineurin signaling and promoting PI3K/Akt/MDM2-mediated calcineurin degradation [#15, #16], and mediates pro-myelination neuroprotection in oligodendrocytes through PI3K/Akt/mTOR [#12]. A germline ESR2 frameshift mutation has been linked to tumor formation through loss of ERα repression [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that a second estrogen receptor exists, defining ERβ as a ligand-activated transcription factor distinct from ERα with weaker transactivation.\",\n      \"evidence\": \"Degenerate PCR cloning, sequence homology, and ERE-reporter transactivation in CHO cells with pharmacological antagonism\",\n      \"pmids\": [\"8769313\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous target genes not yet identified\", \"Physiological tissue role undefined\", \"Basis for lower transactivation vs ERα unexplained\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved why ERβ and ERα behave differently by showing each adopts distinct ligand-dependent conformations, providing a structural basis for isoform- and ligand-specific activity.\",\n      \"evidence\": \"Peptide affinity selection probing apo- and ligand-bound receptor surfaces with estradiol and 4-OH tamoxifen\",\n      \"pmids\": [\"10097152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No atomic-resolution structure reported here\", \"Functional consequence of conformations in vivo not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined ERβ's in vivo role as an antiproliferative modulator opposing ERα-mediated estrogen responses in the uterus.\",\n      \"evidence\": \"BERKO knockout mice with immunohistochemistry, protein quantification, and hormonal challenge\",\n      \"pmids\": [\"10823946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of opposition not resolved here\", \"Direct vs indirect effects on ERα targets unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed ERβ directly suppresses tumor cell proliferation and invasion in an ERα-null context, distinguishing its target gene program (induces p21, pS2, TGFα; not c-myc) from ERα.\",\n      \"evidence\": \"Adenoviral ERβ expression in MDA-MB-231 cells with reporter, proliferation, and invasion assays\",\n      \"pmids\": [\"11517191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand-independent growth inhibition mechanism not defined\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Consolidated that ERβ forms functional heterodimers with ERα and inhibits ERα-mediated transcription across promoter and cell-type contexts.\",\n      \"evidence\": \"Review summarizing transfection and reporter coexpression studies\",\n      \"pmids\": [\"14993442\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level synthesis, not new primary data\", \"Structural detail of heterodimer not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed a chaperone-like function whereby ERβ facilitates ERα nuclear re-entry after E2-induced export, restoring estrogen responsiveness.\",\n      \"evidence\": \"BrdU labeling, subtype-specific immunohistochemistry, and ERβ-knockout mice with hormonal challenge\",\n      \"pmids\": [\"14762170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery of ERα re-import unknown\", \"Whether ERβ acts directly on ERα trafficking untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the dimerization rules of ERβ isoforms, establishing ERβ1 as the obligatory partner and showing helix-12-deficient isoforms modulate rather than independently activate.\",\n      \"evidence\": \"Molecular modeling with reporter and co-immunoprecipitation dimerization assays across isoforms\",\n      \"pmids\": [\"16938840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of isoform heterodimers not established\", \"Tissue-specific isoform stoichiometry unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Distinguished ERβ from ERα non-genomically, showing E2–ERβ activates p38/MAPK to drive apoptosis rather than engaging survival ERK/PI3K-AKT pathways.\",\n      \"evidence\": \"Kinase activation, caspase-3, and PARP cleavage assays across HepG2, DLD1, and HeLa cells\",\n      \"pmids\": [\"15389627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Membrane receptor pool/scaffold mediating signaling unidentified\", \"Link to genomic ERβ outputs unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mechanistically dissected ERβ repression of ERα-driven BRCA2 transcription via competition at Sp1 sites and reduced histone acetylation.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP, reporter assays, and Sp1-site mutagenesis\",\n      \"pmids\": [\"18765668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalizability beyond BRCA2 promoter untested here\", \"Coactivator quantitation indirect\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed ERβ directly suppresses ERα gene expression by binding non-classical AP-1/Sp1 and classic ERE motifs in ERα promoters, creating a feedback loop controlling estrogen sensitivity.\",\n      \"evidence\": \"siRNA knockdown, overexpression, ChIP, and promoter analysis in endometriotic stromal cells\",\n      \"pmids\": [\"19001520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors at AP-1/Sp1 sites not identified\", \"Restricted to endometriotic stromal context\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended ERβ function to behavior and neuroimmune regulation, implicating it in anxiolysis and in non-hematopoietic control of autoimmune neuroinflammation.\",\n      \"evidence\": \"ERβ-knockout/heterozygous mice in anxiety tests and EAE with reciprocal bone marrow chimeras and cytokine assays\",\n      \"pmids\": [\"18996135\", \"15161628\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Anxiolytic effect partial and dose-restricted, single lab\", \"Non-hematopoietic cell type mediating EAE heterosis unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified an anti-inflammatory mechanism whereby ERβ agonism suppresses macrophage iNOS by blocking NF-κB p65 nuclear translocation independent of ERK.\",\n      \"evidence\": \"ERB-041 and U0126 treatment with immunoblotting in endometriosis peritoneal macrophages\",\n      \"pmids\": [\"19447495\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ERβ–NF-κB interaction not demonstrated\", \"Single lab, pharmacological only\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated cell-autonomous ERβ requirement in oligodendrocytes for agonist-driven remyelination via PI3K/Akt/mTOR.\",\n      \"evidence\": \"Oligodendrocyte-specific conditional ERβ knockout in EAE with electrophysiology, immunostaining, and pathway Western blots\",\n      \"pmids\": [\"24191028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in oligodendrocytes not defined\", \"Whether effect is genomic or non-genomic unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Separated ERβ-specific circadian effects from ERα, showing ERβ activation reshapes locomotor activity distribution and phase responses.\",\n      \"evidence\": \"Selective agonists (PPT vs DPN) in ovariectomized mice with wheel-running and phase-response analysis\",\n      \"pmids\": [\"24735329\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Brain locus and target genes unidentified\", \"Single lab pharmacological dissection\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided human genetic proof that ERβ loss causes unopposed ERα signaling and tumorigenic proliferation, including de-repression of the RET promoter.\",\n      \"evidence\": \"Exome sequencing of a c.948delT frameshift with ERE/RET reporter, proliferation assays, and tumor immunostaining\",\n      \"pmids\": [\"26945007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single patient/mutation\", \"Full spectrum of de-repressed targets not catalogued\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established ERβ's DNA-binding transcriptional activity as indispensable for ovulation and identified Kiss1 as a direct granulosa-cell target activated via promoter/enhancer EREs and gonadotropin-driven ERK phosphorylation.\",\n      \"evidence\": \"Esr2-null and DBD-mutant rats, granulosa-cell RNA-seq, ChIP, ERE-mutagenesis reporter assays, and kinase assays\",\n      \"pmids\": [\"29580824\", \"30277501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional hierarchy among the 1,696 DEGs unresolved\", \"Role of ERβ phosphorylation site mutants not directly tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined cardioprotective mechanisms by which E2/ERβ limits hypertrophy through Ca²⁺-calcineurin inhibition and limits apoptosis via PI3K/Akt/MDM2-mediated calcineurin degradation.\",\n      \"evidence\": \"ERβ overexpression in H9c2 cardiomyoblasts with pharmacological epistasis (CsA, BAPTA) and Western blots\",\n      \"pmids\": [\"28863192\", \"28441761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genomic vs non-genomic contribution not separated\", \"In vivo cardiac validation absent\", \"Apoptosis arm single lab/single method\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined ERβ as a transcription-dependent gatekeeper of the primordial follicle reserve, suppressing AKT/ERK/mTOR follicle activation, an effect specific to ERβ and not ERα.\",\n      \"evidence\": \"Esr2-null and DBD-mutant rats, ERβ agonist/antagonist (DPN/PHTPP), follicle counting, hormone measurement, and pathway Western blots; CRISPR full-gene-deletion mouse confirming sex-specific reproductive requirement\",\n      \"pmids\": [\"32141511\", \"32703416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct intrafollicular target genes controlling activation unconfirmed\", \"Cell-of-origin (granulosa vs oocyte) of the signal unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended ERβ as a transcriptional regulator into neural and joint contexts, repressing miR-10a to control BDNF/synaptic plasticity and acting via an LXA4/ESR2/LPAR3/Nrf2 axis to inhibit ferroptosis.\",\n      \"evidence\": \"Postpartum depression mouse models, primary neurons, luciferase reporters; KOA rat models with LPAR3 gain/loss and PHTPP antagonism\",\n      \"pmids\": [\"39588356\", \"38754271\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ERβ binding to miR-10a and LPAR3 loci not shown\", \"Single lab for each axis\", \"Causal hierarchy within multi-node pathways inferred\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ERβ's genomic (ERE/Sp1/AP-1 binding) and non-genomic (p38, PI3K/Akt) activities are integrated within a given cell to specify antiproliferative, pro-apoptotic, or protective outcomes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking conformation, dimer composition, and signaling output\", \"Tissue-specific coregulator complements largely uncatalogued\", \"Endogenous direct target gene atlas incomplete outside ovary\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 8, 11, 14, 17, 18, 23]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 8, 11, 17, 18]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [6, 15, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 4, 7, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 4, 8]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [8, 11, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 15, 16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 8, 11, 17, 18]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [17, 18, 19, 20]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 16, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ESR1\", \"CBP/p300\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}